Chugai, DSP end WT1 cancer vaccine tie-up
This article was originally published in Scrip
Dainippon Sumitomo Pharma (DSP) and Roche's Japanese subsidiary Chugai have ended an agreement for the joint development and commercialization of two peptide therapeutic vaccines for cancer, with DSP to take on future sole responsibility for these.
You may also be interested in...
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.